Inhibrx Biosciences Inc (INBX)
NASDAQ:INBX
US Market

Inhibrx Biosciences Inc (INBX) Income Statement

5 Followers

Inhibrx Biosciences Inc Income Statement

Last quarter (Q ), Inhibrx Biosciences Inc's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q, Inhibrx Biosciences Inc's net income was $-49.27M. See Inhibrx Biosciences Inc’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 1.78M$ 1.63M$ 2.19M$ 7.23M$ 12.89M
Cost of Revenue
-----
Gross Profit
$ 1.78M$ 1.63M$ 2.19M$ 7.23M$ 12.89M
Operating Expense
$ 226.51M$ 154.96M$ 131.31M$ 83.80M$ 80.33M
Operating Income
$ -224.73M$ -153.33M$ -129.12M$ -76.56M$ -67.44M
Net Non Operating Interest Income Expense
$ 5.08M-$ -16.11M$ -5.22M$ -8.16M
Other Income Expense
$ 22.07M$ 1.63M$ 16.11M$ -14.00K$ 513.00K
Pretax Income
$ -240.08M$ -154.96M$ -145.22M$ -81.77M$ -76.12M
Tax Provision
$ 3.00K$ 3.00K$ 3.00K$ 2.00K$ 3.00K
Earnings From Equity Interest Net Of Tax
$ -1.63M---$ -487.00K
Net Income Common Stockholders
$ -241.72M$ -154.96M$ -145.23M$ -81.77M$ -76.12M
Basic EPS
$ -7.37$ -10.88$ -3.62$ -2.15$ -3.01
Diluted EPS
$ -7.37$ -10.88$ -3.62$ -2.15$ -3.01
Basic Average Shares
$ 160.00M$ 14.55M$ 40.11M$ 38.01M$ 25.26M
Diluted Average Shares
$ 160.00M$ 14.55M$ 40.11M$ 38.01M$ 25.26M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 46.66M$ 154.96M$ 131.31M$ 83.80M$ 80.33M
Net Income From Continuing And Discontinued Operation
$ -241.72M$ -154.96M$ -145.23M$ -81.77M$ -76.12M
Normalized Income
$ -89.69M$ -113.90M---
Interest Expense
-----
EBIT
$ -148.11M$ -154.96M$ -145.22M$ -81.77M$ -76.12M
EBITDA
$ -48.91M$ -153.77M$ -140.55M$ -79.34M$ -64.91M
Currency in USD

Inhibrx Biosciences Inc Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis